학술논문

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.
Document Type
Article
Source
Investigational New Drugs; Jun2020, Vol. 38 Issue 3, p765-775, 11p
Subject
FECAL analysis
ANTINEOPLASTIC agents
BLOOD plasma
ENZYME inhibitors
LIQUID chromatography
MASS spectrometry
MOLECULAR structure
PHARMACOLOGY
RADIOACTIVITY
TRANSFERASES
TUMORS
URINALYSIS
ABSORPTION
PHARMACODYNAMICS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)